For 1605 BRCA2 GPV carriers, RRSO carried out before or after age 45 did not decrease breast cancer risk (HRbefore 45 years: 1.07, 95% CI: 0.69–1.64, HRafter age 45: 0.68, 95% CI: 0.40–1.15), followed-up for a mean of 4.9 years. The gene discussed is BRCA2; the disease is breast cancer.